Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3694, Japan.
Department of Pharmacy, Iwate Medical University Hospital, 2-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3695, Japan.
Cancer Chemother Pharmacol. 2024 Apr;93(4):319-328. doi: 10.1007/s00280-023-04619-3. Epub 2023 Nov 28.
Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders.
This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication.
The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: "Grade 1 and lower," and "Grade 2 and higher." The skin parameters were compared between these groups. The results showed that in the "Grade 2 and higher" group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the "Grade 1 and lower" group. However, the two groups showed no significant differences in hydration or sebum levels at any time point.
TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.
接受抗表皮生长因子受体（EGFR）抗体药物治疗的癌症患者常出现痤疮样皮疹，往往需要停药。然而，抗 EGFR 抗体药物给药引起的皮肤参数的具体变化尚不清楚。因此，本研究旨在纵向和定量评估抗 EGFR 抗体药物引起的皮肤参数（经皮水分流失[TEWL]、水合水平和皮脂水平）的变化，并研究其作为皮肤疾病控制标志物的潜力。
本前瞻性研究纳入了 12 例首次接受抗 EGFR 抗体药物治疗的结直肠癌患者。评估项目包括痤疮样皮疹的分级和皮肤参数（TEWL、水合水平和皮脂水平），在用药后长达 6 周进行观察。
根据抗 EGFR 抗体药物引起的痤疮样皮疹的严重程度，将入组患者分为两组：“1 级及以下”和“2 级及以上”。比较两组之间的皮肤参数。结果显示，在“2 级及以上”组中，用药第 2 周时面部（Tewl）、胸部（基线、用药第 2 周和第 6 周）和背部（用药第 2 周）的 TEWL 明显高于“1 级及以下”组。然而，两组在任何时间点的水合或皮脂水平均无显著差异。
TEWL 可作为抗 EGFR 抗体药物治疗癌症时引起痤疮样皮疹的标志物。
